Next Article in Journal
Combating Ischemia-Reperfusion Injury with Micronutrients and Natural Compounds during Solid Organ Transplantation: Data of Clinical Trials and Lessons of Preclinical Findings
Next Article in Special Issue
NTRK Gene Fusion Detection in Atypical Spitz Tumors
Previous Article in Journal
Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?
Previous Article in Special Issue
Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 19
10.3390/ijms221910674
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Bona Fide Tumor Suppressor Genes Hypermethylated in Melanoma: A Narrative Review

Int. J. Mol. Sci. 2021, 22(19), 10674; https://doi.org/10.3390/ijms221910674
by Canan Güvenç 1,*, Fien Neckebroeck 1, Asier Antoranz 2, Marjan Garmyn 1, Joost van den Oord 2 and Francesca Maria Bosisio 2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2021, 22(19), 10674; https://doi.org/10.3390/ijms221910674
Submission received: 27 August 2021 / Revised: 27 September 2021 / Accepted: 30 September 2021 / Published: 1 October 2021
(This article belongs to the Special Issue Molecular Biology, Immune Surveillance and Progressive Disease: New Insights in Melanoma Research)

Round 1

Reviewer 1 Report

In this manuscript, the authors elaborated a review on  24 genes (bona fide TSGs )silenced by promoter CpG-island hypermethylation in cutaneous malignant melanoma (CMM).

Firstly, the authors reported on the importance of this theme and the results obtained after a systematic review of the data published on diverse platforms.

The authors discussed the genes that were methylated and deleted in melanoma.

In general, the data are well corroborated and discussed, and convincingly shows that the characterization of the DNA methylation mechanisms that initiate and promote human melanoma development may lead to the identification of the biomarkers that could be used for prevention, early detection, treatment, and monitoring of the progression of this malignancy.

The manuscript is well written, concise and the appropriate references are cited.

The authors need to address the below comments to strengthen the quality of the manuscript:

Follow the template of the journal to correct the References (e.g. 12, 13, 24, 26, 49, 52).

Add reference/s to the statements from the phrase from page 9: “Also, we observed a link between p53 pathway and SYK but also with RASSF8.”.

Include a Conclusion part or A Perspective part for more information on the theme.

Check the minor spelling mistakes: fide not fida at page 8, and Fig. 1.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

This review Bona fide tumor suppressor genes hypermethylated in melanoma: a narrative review summarizes recent findings dealing promoter hypermethilation in melanoma. The manuscript is well-written, but some issues to fix were found.

I recommend increasing the time frame up to years 2020-2021 to improve the quality of presented review.

Second, please explain why have you exclude TERT, p16,  and some other genes involved in melanoma progression. Is that gene list sufficient for the review?

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

You have address all the issues. Thank you.

Back to TopTop